NCT05048797 2025-12-23A Study to Investigate the Efficacy and Safety of Trastuzumab Deruxtecan as the First Treatment Option for Unresectable, Locally Advanced/Metastatic Non-Small Cell Lung Cancer With HER2 MutationsAstraZenecaPhase 3 Active not recruiting454 enrolled